{"classes":[{"categories":[{"measurements":[{"comment":"Standard deviation was not evaluable since only 1 participant was evaluated.","groupId":"OG001","spread":"NA","value":"65434.0"},{"groupId":"OG002","spread":"12010.9","value":"72632.0"},{"comment":"Standard deviation was not evaluable since only 1 participant was evaluated.","groupId":"OG003","spread":"NA","value":"43803.0"},{"comment":"Standard deviation was not evaluable since only 1 participant was evaluated.","groupId":"OG004","spread":"NA","value":"61773.0"},{"groupId":"OG005","spread":"13614.0","value":"68141.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"18"}],"units":"Participants"}],"title":"Peripheral Blood: Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14131.9","value":"38402.7"},{"comment":"Standard deviation was not evaluable since only 1 participant was evaluated.","groupId":"OG001","spread":"NA","value":"78356.0"},{"comment":"Standard deviation was not evaluable since only 1 participant was evaluated.","groupId":"OG003","spread":"NA","value":"76264.0"},{"comment":"Standard deviation was not evaluable since only 1 participant was evaluated.","groupId":"OG004","spread":"NA","value":"52495.0"},{"groupId":"OG005","spread":"25479.5","value":"33259.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"7"}],"units":"Participants"}],"title":"Peripheral Blood: Partial Response"},{"categories":[{"measurements":[{"comment":"Standard deviation was not evaluable since only 1 participant was evaluated.","groupId":"OG002","spread":"NA","value":"38939.0"},{"comment":"Standard deviation was not evaluable since only 1 participant was evaluated.","groupId":"OG003","spread":"NA","value":"84157.0"},{"groupId":"OG005","spread":"9644.6","value":"46089.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"title":"Peripheral Blood: Stable Disease"},{"categories":[{"measurements":[{"comment":"Standard deviation was not evaluable since only 1 participant was evaluated.","groupId":"OG004","spread":"NA","value":"24645.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}],"units":"Participants"}],"title":"Peripheral Blood: ProgressiveDisease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"33"}],"units":"Participants"}],"description":"Participants malignant cells (peripheral blood) were tested for cluster of differentiation 22 (CD22) expression by fluorescence-activated cell sorter (FACS) analysis.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received IV 5 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued until complete response (CR), progressive disease (PD), initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG000","title":"5 mcg/kg"},{"description":"Participants received IV 10 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG001","title":"10 mcg/kg"},{"description":"Participants received IV 20 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG002","title":"20 mcg/kg"},{"description":"Participants received IV 30 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG003","title":"30 mcg/kg"},{"description":"Participants received IV 40 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG004","title":"40 mcg/kg"},{"description":"Participants received IV 50 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG005","title":"50 mcg/kg"}],"paramType":"MEAN","populationDescription":"Safety population included all participants who received any treatment of moxetumomab pasudotox.","reportingStatus":"POSTED","timeFrame":"Prior to enrollment during screening, and for participants still having malignant cells, the test was to be repeated prior to each cycle of therapy, at the end of treatment, and end of the study (approximately 8 years)","title":"CD22 Expression Levels From Peripheral Blood by Best Response","type":"SECONDARY","unitOfMeasure":"sites per cell"}